CV Sciences Reports Third Quarter Revenue of $3.3 Million

Reuters

2025/11/14

CV Sciences Reports Third Quarter Revenue of $3.3 Million

CV Sciences Inc. reported revenue of $3.3 million for the third quarter of 2025, down from $3.9 million in the same period of 2024 and $3.6 million in the second quarter of 2025. Gross margin was 48.5% for the third quarter of 2025, compared to 46.0% in the third quarter of 2024 and 50.9% in the previous quarter. The company ended the quarter with a cash balance of $0.4 million, compared to $0.5 million at the end of 2024. Adjusted EBITDA showed a loss of $0.1 million for the third quarter of 2025, compared to a loss of $0.1 million in the same period last year and a positive $0.1 million in the previous quarter. During the quarter, CV Sciences expanded its product offering with the launch of Ignite, a men's performance formula.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CV Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102176) on November 13, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583116235"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583116235\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583116235?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583116235","market":"fut","top_or_hot":-1,"title":"CV Sciences Reports Third Quarter Revenue of $3.3 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CV Sciences Reports Third Quarter Revenue of $3.3 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CV Sciences Inc. reported revenue of $3.3 million for the third quarter of 2025, down from $3.9 million in the same period of 2024 and $3.6 million in the second quarter of 2025. Gross margin was 48.5% for the third quarter of 2025, compared to 46.0% in the third quarter of 2024 and 50.9% in the previous quarter. The company ended the quarter with a cash balance of $0.4 million, compared to $0.5 million at the end of 2024. Adjusted EBITDA showed a loss of $0.1 million for the third quarter of 2025, compared to a loss of $0.1 million in the same period last year and a positive $0.1 million in the previous quarter. During the quarter, CV Sciences expanded its product offering with the launch of Ignite, a men's performance formula.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CV Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102176) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CV Sciences Reports Third Quarter Revenue of $3.3 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCV Sciences Reports Third Quarter Revenue of $3.3 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 05:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CV Sciences Reports Third Quarter Revenue of $3.3 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CV Sciences Inc. reported revenue of $3.3 million for the third quarter of 2025, down from $3.9 million in the same period of 2024 and $3.6 million in the second quarter of 2025. Gross margin was 48.5% for the third quarter of 2025, compared to 46.0% in the third quarter of 2024 and 50.9% in the previous quarter. The company ended the quarter with a cash balance of $0.4 million, compared to $0.5 million at the end of 2024. Adjusted EBITDA showed a loss of $0.1 million for the third quarter of 2025, compared to a loss of $0.1 million in the same period last year and a positive $0.1 million in the previous quarter. During the quarter, CV Sciences expanded its product offering with the launch of Ignite, a men's performance formula.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CV Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102176) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVSI","symbol_name":"CV Sciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL4rcy4X:1","article_id":"2583116235","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583116235","pubTimestamp":1763067626,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CV Sciences Inc. reported revenue of $3.3 million for the third quarter of 2025, down from $3.9 million in the same period of 2024 and $3.6 million in the second quarter of 2025. Gross margin was 48.5% for the third quarter of 2025, compared to 46.0% in the third quarter of 2024 and 50.9% in the previous quarter. The company ended the quarter with a cash balance of $0.4 million, compared to $0.5 million at the end of 2024. Adjusted EBITDA showed a loss of $0.1 million for the third quarter of 2025, compared to a loss of $0.1 million in the same period last year and a positive $0.1 million in the previous quarter. During the quarter, CV Sciences expanded its product offering with the launch of Ignite, a men's performance formula.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CVSI":"CV Sciences, Inc.","BK4183":"个人用品"},"translate_title":"CV Sciences报告第三季度营收为330万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVSI":0.9},"content_text":"CV Sciences Reports Third Quarter Revenue of $3.3 Million\n    \n\n        CV Sciences Inc. reported revenue of $3.3 million for the third quarter of 2025, down from $3.9 million in the same period of 2024 and $3.6 million in the second quarter of 2025. Gross margin was 48.5% for the third quarter of 2025, compared to 46.0% in the third quarter of 2024 and 50.9% in the previous quarter. The company ended the quarter with a cash balance of $0.4 million, compared to $0.5 million at the end of 2024. Adjusted EBITDA showed a loss of $0.1 million for the third quarter of 2025, compared to a loss of $0.1 million in the same period last year and a positive $0.1 million in the previous quarter. During the quarter, CV Sciences expanded its product offering with the launch of Ignite, a men's performance formula.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CV Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102176) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}